PPMDB.org logo

The Precautionary and Prohibited Medications Database

Maintained by a collaboration of the University at Buffalo Pharmacology Specialty Laboratory and Frontier Science & Technology Research Foundation

 
Medications Tenofovir Disoproxil Fumarate and Ribavirin
Designation Unknown or no reaction
Last updated 19-Jul-2018
Interaction History
Effect on concentration Tenofovir Disoproxil Fumarate: No change

Ribavirin: No change
Pharmacologic effect Tenofovir Disoproxil Fumarate: N/A

Ribavirin: N/A
Pharmacologic effect applies to drugs in the same class Tenofovir Disoproxil Fumarate:

Ribavirin:
Pharmacologic effect description Tenofovir Disoproxil Fumarate:

Ribavirin:
Potential pharmacokinetic effect Tenofovir Disoproxil Fumarate: N/A

Ribavirin: N/A
Potential pharmacokinetic effect applies to drugs in the same class Tenofovir Disoproxil Fumarate:

Ribavirin:
Potential pharmacokinetic mechanism Tenofovir Disoproxil Fumarate:

Ribavirin:

Summary

Sources

Tenofovir Disoproxil Fumarate versus Ribavirin

Study Design
This was a 36 day, open-label, fixed-sequence, multiple dose, drug interaction study in 23 healthy adults to evaluate the effects of multiple doses of tenofovir disoproxil fumarate on the single dose pharmacokinetics of ribavirin. Subjects received a 600 mg once daily dose of ribavirin on days 1 and 22, and 300 mg daily doses of tenofovir disoproxil fumarate on days 17-24. Pharmacokinetic sampling was done on days 1 through 4, and 22 through 25.  
Study Results
Pharmacokinetics of ribavirin was not altered by coadministration with tenofovir disoproxil fumarate as the point estimates (day 22 [test treatment]/day 1 [reference treatment] and the 90% confidence interval for the maximum observed concentration (0.95, 88.7 101) and AUC (1.12, 106 117). Both were within the equivalence bounds of 80% - 125%. Tenofovir pharmacokinetics after administration of ribavirin were similar to those observed in previous studies.  
Study Conclusions
The study authors concluded that coadministration of ribavirin and tenofovir disoproxil fumarate does not result in substantial changes to their individual pharmacokinetic profiles.  
References
Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. Journal Of Clinical Pharmacology. 2006; 5: 559-566.  

Study information updated: 19-Jul-2018